AI Research TTEXLETTE_estimatesmacro:brent_daily

TTE vs XLE forward 20-day excess: joint EPS-revision/Brent condition is untestable; Brent-tape-only comparison shown

0
Joint-condition eligible days

The joint condition the question asks for — analyst estimates revised up while crude rises — has no history to test. Over the past three years, zero sessions qualified, because the estimate data holds one current snapshot per quarter rather than the 30-day revision path needed to measure it.

What survived is the Brent leg alone, and it came back cleaner than expected. Across 306 sessions when crude's prior 20-day return was positive, TTE beat XLE by an average 0.86% over the next 20 sessions; when crude wasn't rising, TTE lagged by 0.62%. TTE won 61% of the positive-crude windows.

That's a real tilt, but it's a crude-tape effect, not evidence for slower repricing in a European integrated. The revision thesis stays open, untested. The full breakdown, including the Welch tests, is below.

The research question

Over the past ~3 years, when TTE's next-quarter consensus EPS estimate is revised upward by at least 1% over the prior 30 days while Brent crude's 20-day return is positive, does TTE outperform XLE over the next 20 trading sessions? I expect positive analyst revisions into a rising crude tape to be repriced more slowly in a European integrated than in U.

How this was measured

Resampled TTE and XLE minute bars to daily closes, aligned inner on trading dates, and computed close-to-close forward 20-session excess return as TTE minus XLE. Brent crude daily values were reindexed to the trading calendar and the 20-session return was lagged one day for T+1 publication. Days were split by whether the lagged Brent 20-day return was positive, and one-sample plus Welch tests were used on the forward excess. The requested TTE 30-day EPS revision condition was not applied historically because TTE_estimates lacks within-quarter revision history; only the current as-of-today revision snapshot is reported.

The key numbers

Joint-condition eligible days
0
No historical within-quarter 30-day EPS revision series in TTE_estimates
Brent-positive days analyzed
306
Window 2023-10-31 to 2026-08-03
TTE-XLE mean fwd 20d excess (Brent-positive)
0.8626%
N=306 Brent-positive sessions
TTE-XLE mean fwd 20d excess (Brent-non-positive)
-0.6157%
N=384 non-positive sessions
TTE-XLE mean fwd 20d excess (all days)
0.0399%
N=690 overlapped sessions
Brent-positive outperformance frequency
61.11%
Share of Brent-positive days with TTE beating XLE over next 20 sessions
Brent-positive one-sample t-stat vs 0
3.266
Positive means TTE beat XLE on average in Brent-positive tape
Brent-positive one-sample p-value
0.0012
H0 mean=0; p=0.0012 < 0.05 -> TTE-XLE excess differs from zero
Brent-positive vs non-positive Welch p-value
0.0000
p=0.0000 < 0.05 -> Brent tape splits TTE-XLE forward excess
Current TTE next-quarter 30d EPS revision
-1.9797%
Next quarterly row (estimate_date=2026-09-30)
Current Brent 20d return
18.7724%
Snapshot, not used for historical backtest

Reading the numbers

Strictly as asked, zero days qualified because there is no historical 30-day EPS revision series to combine with Brent. On the Brent leg, TTE beat XLE by 0.86% on average over the next 20 sessions when Brent's 20-day return was positive, versus losing 0.62% when it wasn't; the gap is clear.

The charts

Forward 20-day TTE minus XLE return by Brent tape
What this chart says

This box plot splits the next-20-session TTE-minus-XLE return into three groups: Brent up, Brent flat-or-down, and all days. The key detail is the average: +0.86% when Brent's 20-day return was positive versus -0.62% when it wasn't, with all days near flat at +0.04%. The distributions still overlap heavily and the Brent-up group's outcomes range from about -16.6% to +15.5%, so the tape tilts the odds rather than determining the result. This supports the Brent leg of your question, but not the analyst-revision leg, which had zero testable history.

Brent 20d signal vs TTE-XLE forward 20d excess
What this chart says

The scatter plots each day's lagged Brent 20-day return against the following 20-session TTE-minus-XLE excess, with 690 observations. Brent readings span a very wide range, from -32.6% to +70.3%, while the forward excess stays between -20.2% and +15.5% and averages just +0.04%. The cloud is widely dispersed rather than a tight line, so a single crude reading does not map one-for-one to the next month's relative performance. That is why the cleaner read is regime averages, and why the full joint condition remains untested with zero eligible days.

Forward 20-day TTE minus XLE return by Brent tape

GroupNMeanMedianStdPositive share
Brent 20d > 03060.00860.010.04620.6111
Brent 20d <= 0384-0.0062-0.00010.04290.5
All days6900.00040.00550.0450.5493

The takeaway

The question as asked can't be answered: there are zero historical days in the past three years where TTE's 30-day EPS revision could even be measured, because the estimate data only holds a single current snapshot per quarter rather than a revision history — so no joint revision-and-Brent test was run. What could be tested is the Brent leg alone, and it came back unusually clean. On the 306 sessions when Brent's prior 20-day return was positive, TTE beat XLE over the following 20 sessions by an average of 0.86%, versus a 0.62% lag on the 384 days when Brent wasn't rising — a gap that's very unlikely to be noise (Welch p ≈ 0.00002). The Brent-positive group's outperformance on its own also clears zero (p = 0.001), and TTE won 61% of those windows versus a literal 50-50 coin flip when Brent was flat or down. That's a real signal, not a lean — but it is a Brent-tape effect, not the analyst-revision effect you were asking about, so it doesn't confirm your thesis about slower repricing of European integrateds. Practically: rising crude does seem to tilt the next month in TTE's favor against XLE, and it's worth testing properly once a revision history exists — but today the revision half of the setup is simply unmeasured, and the current snapshot (revision at -1.98%, Brent 20-day at +18.77%) is a starting condition, not evidence.

The fine print